American Oncology Partners of Maryland, PA

Summary

American Oncology Partners of Maryland, PA is a medical facility located in Bethesda, Maryland. This center is recognized for care of Chronic Lymphocytic Leukemia, Lymphoma, Cancer, Lung Cancer, Multiple Myeloma and other specialties. American Oncology Partners of Maryland, PA is involved with conducting 48 clinical trials across 88 conditions. There are 4 research doctors associated with this hospital, such as Mark Goldstein, MD, Ralph Boccia, Bruce D Cheson, and Ralph Vincent Boccia.

Top PIs

Clinical Trials running at American Oncology Partners of Maryland, PA

Chronic Lymphocytic Leukemia

Myelofibrosis

Follicular Lymphoma

Lymphoma

Lung Cancer

Mixed-Cell Lymphoma

Cancer

Breast Cancer

Marginal Zone Lymphoma

MALT Lymphoma

BGB-16673

for Chronic Lymphocytic Leukemia

The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).

Recruiting

2 awards

Phase 3

4 criteria

Pirtobrutinib vs Ibrutinib

for Chronic Lymphocytic Leukemia

The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part 2 of this study evaluates pirtobrutinib monotherapy in treatment-naïve participants with CLL/SLL with 17p deletions. Participation could last up to six years for Part 1. Participation could last up to 2 years for Part 2.

Recruiting

2 awards

Phase 3

Venetoclax + Obinutuzumab/Acalabrutinib

for Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse events and change in disease activity will be assessed. Venetoclax in combination with obinutuzumab or acalabrutinib is being investigated in the treatment of CLL. Study doctors put the participants in 1 of 4 groups, called treatment arms. Participants will receive oral venetoclax in combination with intravenously (IV) infused obinutuzumab or oral acalabrutinib at in different dosing schemes as part of treatment. Approximately 170 adult participants with CLL who are being treated with venetoclax will be enrolled in the study in approximately 80 sites worldwide. Participants in Arm A will receive oral venetoclax in combination with IV infused obinutuzumab, with a 5 week venetoclax ramp up. Participants in Arm B will receive oral venetoclax in combination with oral acalabrutinib, with a 5 week venetoclax ramp up. Participants in Arm C and Arm D will receive oral venetoclax in combination with oral acalabrutinib, with differing venetoclax ramp up periods. The total study duration is approximately 28 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Recruiting

2 awards

Phase 3

3 criteria